Citius Oncology, Inc. ("Citius Oncology" or the "Company") , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today ...
From data quality and AI readiness to the realities of clinical translation, industry leaders share where precision still ...
One of life's many mysteries is how it ended up choosing only a set of 20 amino acids to build proteins for its wide catalog ...
These findings are important because they suggest that more selective JAK inhibition, particularly targeting JAK1 or JAK2, can effectively reduce organ pathology and pathogenic IFN-γ-producing immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results